Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model

Oxford Outcomes, Oxford, UK. Electronic address: .
Vaccine (Impact Factor: 3.49). 12/2012; 31(6). DOI: 10.1016/j.vaccine.2012.12.010
Source: PubMed

ABSTRACT This study uses a dynamic influenza transmission model to directly compare the cost-effectiveness of various policies of annual paediatric influenza vaccination in England and Wales, varying the target age range and level of coverage. The model accounts for both the protection of those immunised and the indirect protection of the rest of the population via herd immunity. The impact of augmenting current practice with a policy to vaccinate pre-school age children, on their own or with school age children, was assessed in terms of quality adjusted life years and health service costs. Vaccinating 2-18-year olds was estimated to be the most cost-effective policy in an incremental cost-effectiveness analysis, at an assumed annual vaccine uptake rate of 50%. The mean incremental cost-effectiveness ratios for this policy was estimated at £251/QALY relative to current practice. Paediatric vaccination would appear to be a highly cost-effective intervention that directly protects those targeted for vaccination, with indirect protection extending to both the very young and the elderly.

Download full-text


Available from: Richard Pitman, Jan 17, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Vaccination remains the most effective prophylactic intervention for infectious disease in the healthcare professional's toolkit. However, the efficacy and effectiveness of vaccines decrease with age. This becomes most apparent after an individual reaches 65-70 years old, and results from complex changes in the immune system that occur during aging. As such, new vaccine formulations and strategies that can accommodate age-related changes in immunity are required to protect this expanding population. Here, we summarize the consequences of immunosenescence on vaccination and how novel vaccination strategies can be designed to accommodate the aging immune system. We conclude that current vaccination protocols are not sufficient to protect our aging population and, in some cases, are an inefficient use of healthcare resources. However, researchers and clinicians are developing novel vaccination strategies that include modifying who and when we vaccinate and capitalize on existing vaccines, in addition to formulating new vaccines specifically tailored to the elderly in order to remedy this deficiency.
    Frontiers in Immunology 06/2013; 4:171. DOI:10.3389/fimmu.2013.00171
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Influenza is an important cause of morbidity and mortality, especially in combination with secondary bacterial infections.1-3 Annual influenza vaccination is recommended for everyone at risk by the WHO.4 In recent years, a number of countries have recommended influenza vaccination for all children older than 6 months although the uptake has been variable. The effectiveness of inactivated influenza vaccines in children has been questioned.5 Numerous studies have been published on the subject but outcome measures used vary with some studies using influenza-like-illness while others use culture or PCR-proven influenza, making comparison and meta-analyses difficult. In several randomised clinical trials, live attenuated influenza vaccine (LAIV) has been found safe, effective compared to placebo and consistently more effective than trivalent inactivated vaccine (TIV) in children. In 2012, UK authorities announced plans to offer annual LAIV to all children aged 2-17 years and in July 2013 that a single dose of the vaccine will be offered to all 2-year-olds and 3-year-olds from September 2013. Although the evidence base supporting this decision is robust, some important questions remain unanswered. Such a campaign, if carried out successfully, could significantly reduce the burden of disease in children and, since children are thought to be important in the propagation of infection within the population and thus development of influenza epidemics, this initiative may well impact on disease in other age groups through indirect protection. However, few studies quantifying such effects have been done to date. In this paper, aspects of the implementation of universal childhood influenza vaccination are discussed.
    Archives of Disease in Childhood 08/2013; 98(11). DOI:10.1136/archdischild-2013-304681 · 2.91 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Seasonal influenza infections cause a high burden of disease for the whole community every year. Effective vaccines are available and used worldwide in adults and children. Discussion is ongoing as to whether influenza vaccination for children should be implemented in the National Immunization Program (NIP). Is there enough evidence to support routine influenza vaccination in children? In this review we briefly discuss the influenza viruses and the available vaccines. Subsequently, the current data available on influenza vaccination is reviewed and weighed against the Dutch criteria for the introduction of new vaccines into the NIP.
    The Journal of infection 10/2013; DOI:10.1016/j.jinf.2013.09.019 · 4.02 Impact Factor
Show more